论文部分内容阅读
方法:采用转铁蛋白受体单克降抗体(TFR-M)与表阿霉素、顺氯氨铂等化疗药物耦联,经选择性动脉插管、B超导引下门静脉穿刺或胸腹腔直接穿刺灌注,导向治疗伴肝内及门静脉或/和腔静脉转移的原发性肝癌26例与转移性肝癌8例,其中20例同时伴有腹盆腔淋巴结转移,肿大淋巴结数2～12枚不等,肝内转移病灶1～8个不等.结果:瘤体缩小达PR级13例(38.5%),MR级15例(44.1%).特别是门/腔静脉癌栓2例消失,22例缩小(共占92.3%).腹腔淋巴结均见明显缩小或减少.
METHODS: The transferrin receptor monoclonal antibody (TFR-M) was coupled with epirubicin, cisplatin and other chemotherapeutic drugs via selective arterial cannulation, B-guided inferior portal vein puncture, or thoracoabdominal cavity Direct puncture and perfusion, guided treatment of primary hepatocellular carcinoma with intrahepatic and portal vein or/and vena cava metastasis in 26 cases and metastatic liver cancer in 8 cases, of which 20 cases were accompanied by abdominal pelvic lymph node metastasis with 2 to 12 lymphadenopathy nodes. Intrahepatic metastatic lesions ranged from 1 to 8 cases. Results: The tumor size was reduced to 13 cases (38.5%) in PR and 15 cases (44.1%) in MR. In particular, 2 cases of portal vein thrombosis disappeared. 22 cases were reduced (92.3% in total). Abdominal lymph nodes were significantly reduced or reduced.